Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peking Union Medical College Hospital · Chinese Academy of Medical Sciences & Peking Union Medical College · +34 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
149
total citations
- FWCI
- 76.42
- Percentile
- 100%
- References
- 31
Citations per year
Authors
34- DLDomenica LorussoCorresponding
- YXYang Xiang
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
- KHKosei Hasegawa
Saitama International Medical Center, Saitama Medical University
- GSGiovanni Scambia
Istituti di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic
- MLManuel Leiva
Institute of Peruvian Studies
Topics & keywords
Topics
Keywords
- Pembrolizumab
- Medicine
- Placebo
- Chemoradiotherapy
- Cervical cancer
- Internal medicine
- Oncology
- Cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.